Skip to main content Skip to main navigation menu Skip to site footer
Published: 2021-03-16

A systematic review and meta-analysis of the efficacy and safety of remdesivir in COVID-19 patients

R. G. Kar Medical College, Kolkata 700004, West Bengal, India
Department of Mathematics, Mankar College, Mankar, West Bengal 713144, India
Coronavirus Infection, COVID-19, Remdesivir, Randomized Controlled Trial, India


Background: This systematic review compares the efficacy and safety of remdesivir between its recipient and non-recipient COVID-19 patients from the recently published randomized controlled trials (RCT). 

Methods: For eligible trials comparing the above outcomes, a literature search took place in the PubMed database. The reviewed trials data were abstracted and critically appraised using the Cochrane tool. Then, a random-effect meta-analysis followed to compare the risk between the compared interventions in risk ratio (RR). By plying the I2 and Chi2 statistics, the heterogeneity estimation happened. A sensitivity analysis iterated the preliminary meta-analysis using a fixed-effect model.

Results: Two eligible RCTs included in this review sourced data from about 833 COVID-19 patients from 115 hospitals in Asia, Europe, and the US. The risk of bias was primarily low. Random-effect meta-analysis suggested a clinical improvement (RR: 1.09; 95% CI: 1.02, 1.16; P=0.02; I2: 0%) and decrease in the risk of any serious side effects (RR: 0.64; 95% CI: 0.43, 0.94; P<0.001; I2: 0%) in the remdesivir treated COVID-19 patients. The rest of the outcomes did not vary between the juxtaposed interventions.

Conclusion: Evidence-based on early RCTs suggest that remdesivir is a clinically useful and safe drug to treat COVID-19 patients.


Download data is not yet available.

How to Cite

Saha S, Saha S. A systematic review and meta-analysis of the efficacy and safety of remdesivir in COVID-19 patients. jidhealth [Internet]. 2021 Mar. 16 [cited 2023 Apr. 2];4(1):298-303. Available from: